Search research articles
Contact Us
Filters
Showing results (181-190 of 207) with videos related to
Page
of 21
Sort By:
HIV Medicine
|
August 18, 2009
Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial
Jade Ghosn, P Flandre, I Cohen-Codar, et al.
The New England Journal of Medicine
|
October 29, 1998
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team
G Pialoux, F Raffi, F Brun-Vezinet, et al.
Leukemia
|
December 1, 1995
Lack of evidence of HTLV-I/II infection in T CD8 malignant or reactive lymphoproliferative disorders in France: a serological and/or molecular study of 169 cases
N Fouchard, B Flageul, M Bagot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 29, 2000
The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe
G Moyle, A Pozniak, M Opravil, et al.
Revue D'Epidemiologie Et De Sante Publique
|
April 10, 2003
[Management of the bank of biological material in the hospital-based SEROCO and HEMOCO cohorts of HIV-infected patients]
L Meyer, M Gharib, J Lerable, et al.
The Journal of Infectious Diseases
|
January 1, 1997
Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group
M J Mayaux, E Dussaix, J Isopet, et al.
American Journal of Obstetrics and Gynecology
|
September 1, 1996
Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group
L Mandelbrot, M J Mayaux, A Bongain, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 15, 1997
The 25-kDa soluble CD23 activates type III constitutive nitric oxide-synthase activity via CD11b and CD11c expressed by human monocytes
J P Aubry, N Dugas, S Lecoanet-Henchoz, et al.
Antiviral Therapy
|
August 9, 2001
Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment
W Rozenbaum, C Katlama, P Massip, et al.
Clinical Pharmacology and Therapeutics
|
July 3, 1999
Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine
C Michelet, E Bellissant, A Ruffault, et al.
Page
of 21
Search research articles
Search
Showing results (181-190 of 207) with videos related to
Sort By:
Page
of 21
HIV Medicine
|
August 18, 2009
Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial
Jade Ghosn, P Flandre, I Cohen-Codar, et al.
The New England Journal of Medicine
|
October 29, 1998
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team
G Pialoux, F Raffi, F Brun-Vezinet, et al.
Leukemia
|
December 1, 1995
Lack of evidence of HTLV-I/II infection in T CD8 malignant or reactive lymphoproliferative disorders in France: a serological and/or molecular study of 169 cases
N Fouchard, B Flageul, M Bagot, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
March 29, 2000
The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe
G Moyle, A Pozniak, M Opravil, et al.
Revue D'Epidemiologie Et De Sante Publique
|
April 10, 2003
[Management of the bank of biological material in the hospital-based SEROCO and HEMOCO cohorts of HIV-infected patients]
L Meyer, M Gharib, J Lerable, et al.
The Journal of Infectious Diseases
|
January 1, 1997
Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group
M J Mayaux, E Dussaix, J Isopet, et al.
American Journal of Obstetrics and Gynecology
|
September 1, 1996
Obstetric factors and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohorts. SEROGEST French Pediatric HIV Infection Study Group
L Mandelbrot, M J Mayaux, A Bongain, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 15, 1997
The 25-kDa soluble CD23 activates type III constitutive nitric oxide-synthase activity via CD11b and CD11c expressed by human monocytes
J P Aubry, N Dugas, S Lecoanet-Henchoz, et al.
Antiviral Therapy
|
August 9, 2001
Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment
W Rozenbaum, C Katlama, P Massip, et al.
Clinical Pharmacology and Therapeutics
|
July 3, 1999
Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine
C Michelet, E Bellissant, A Ruffault, et al.
Page
of 21